ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Therapeutic Potential of Bone Marrow- and Ovarian/Endometrium-Derived Mesenchymal Stem Cells in Regulating Ovarian Function in a Streptozotocin-Induced Diabetes Mellitus Rat Model.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptozotocin (STZ)-induced pancreatic damage leads to β-cell injury and hyperglycemia, providing a controlled model to study ovarian dysfunction. This study aimed to investigate the potential of mesenchymal stem cells (MSCs) derived from ovary, endometrium, and bone marrow to restore ovarian function in rats with STZ-induced diabetes mellitus, due to their ease of isolation and capacity for differentiation. Fifty female Sprague-Dawley rats were divided into five groups: control, STZ-induced pancreatic damage, and STZ-induced rats treated with ovarian, endometrium, or bone marrow-derived MSCs. Pancreatic damage was induced via intraperitoneal injection of 45 mg/kg STZ in 32 rats. Rats with blood glucose ≥ 200 mg/dL were considered hyperglycemic and monitored for six weeks. MSCs were isolated from healthy donors, cultured, characterized by flow cytometry, and labeled with BrdU. At the third week, 2 × 10⁶ cells in PBS were injected into the ovaries via the endometrial canal. At the sixth week, rats were sacrificed, and ovarian tissues were analyzed histopathologically and immunohistochemically. The results showed that streptozotocin-induced diabetes mellitus led to structural alterations in ovarian follicles. Notably, bone marrow- and ovary-derived MSCs were effective in ameliorating these changes, while endometrium-derived MSCs showed moderate effects. These findings suggest that MSCs have therapeutic potential to mitigate ovarian dysfunction caused by pancreatic β-cell injury and hyperglycemia, highlighting their possible role as a cellular therapy in models of STZ-induced ovarian impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.